InsuletPODD
About: Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
Employees: 3,900
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
94% more first-time investments, than exits
New positions opened: 91 | Existing positions closed: 47
32% more repeat investments, than reductions
Existing positions increased: 291 | Existing positions reduced: 221
4% more funds holding
Funds holding: 670 [Q4 2024] → 697 (+27) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 5 [Q4 2024] → 5 (+0) [Q1 2025]
0% less capital invested
Capital invested by funds: $18.4B [Q4 2024] → $18.3B (-$80M) [Q1 2025]
1.28% less ownership
Funds ownership: 100.42% [Q4 2024] → 99.14% (-1.28%) [Q1 2025]
32% less call options, than puts
Call options by funds: $103M | Put options by funds: $150M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Goldman Sachs David Roman | 25%upside $380 | Buy Initiated | 30 May 2025 |
Raymond James Jayson Bedford | 18%upside $360 | Outperform Maintained | 27 May 2025 |
Citigroup Joanne Wuensch | 25%upside $380 | Buy Maintained | 22 May 2025 |
Wolfe Research Mike Polark | 15%upside $350 | Outperform Upgraded | 13 May 2025 |
Oppenheimer Steven Lichtman | 6%upside $324 | Outperform Maintained | 9 May 2025 |
Financial journalist opinion
Based on 11 articles about PODD published over the past 30 days
